Chukwunonso Nwabufo is the founder of OneDrug Inc. and a multiple award-winning pharmacologist with over six years’ experience in drug development across academia and the pharmaceutical industry. Nwabufo contributed to the development of Remdesivir and Lenacapavir approved for the treatment of COVID-19 and HIV respectively during his tenure at Gilead Sciences. He also contributed to the development of novel compounds under basic science research for the treatment and/or diagnosis of Parkinson’s disease. Nwabufo has received more than 20 awards and recognitions with over C$400K in funding due to his academic, research, and leadership accomplishments. Nwabufo is the author of 15 peer-reviewed scientific papers and 11 industry-standard peer-reviewed reports in support of drug development programs. His research is focused on developing smart point-of-care technologies and methodologies that will empower healthcare providers to individualize patient treatment to help them get well sooner, minimize adverse drug effects, and save healthcare costs. Nwabufo serves as an editorial board member of Drug Metabolism Reviews and Journal of Applied Bioanalysis. He is an abstract screener for PharmSci360 conference and Chair for the Pharmacokinetic, Pharmacodynamic, and Drug Metabolism Community of the American Association of Pharmaceutical Scientists, USA.
University of Toronto
Toronto, Ontario, Canada
Pharmaceutical Sciences
Canadian Institutes of
Canadian Institutes of Health Research